Evidence
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Improved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Dexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
September 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreJune 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
June 9, 2025CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More